Skip to Content


You are viewing the 1st of the 2 courses UPMC Physician Resources permits you to view without registering. To have full access to our FREE courses on our website, please register or log in now.

Drs. Adam Brufsky and Phuong Mai present from the San Antonio Breast Cancer Symposium. Dr. Brufsky discusses Molecular prediction models and Dr. Mai provides and update on breast cancer predisposition genes.

Educational objectives:

Upon completion of this activity, participants should be able to:

  • Implement proper genomic testing for breast cancer recurrence in clinical practice.
  • Follow recommendations for genomic testing for breast cancer recurrence based on prospective clinical trials.
  • Recognize the overall estimated risk level associated with high-risk and moderate-risk breast cancer predisposition genes.
  • Recognize some of the issues related to cancer panel testing

Reading Resources:

  1. Cardoso, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer N Engl J Med 2016; 375:717-729.
  2. RS Jackson, et al. Distant Recurrence Rates in Groups Defined by the AAMC Model using Grade and Hormone Receptor Status, with Comparison to the 21-Gene Recurrence Score Groups. Breast Cancer Treat Res 2016; abstract PD7-03.
  3. Sestak, I et al. Comprehensive Comparison of Prognostic Signatures for Breast Cancer Recurrence in TransATAC Breast Cancer Treat Res 2016; abstract S6-05.
  4. Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016;13(9):581-8
  5. Balmana J, Digiovanni L, Gaddam P, Walsh MF, Joseph V, Stadler ZK, et al. Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. J Clin Oncol. 2016;34(34):4071-8.
  6. National Comprehensive Cancer Network (NCCN). Genetic/familial high-risk assessment: breast and ovarian. Version 2.2017  [01/20/2017]. Available from:


Dr. Mai has reported no relevant relationships with any entities producing health care goods or services

Dr. Brufsky has financial interests with the following any entity or entities producing health care goods or services as indicated below:

Consultant: Agendia, Biotheranostics, nanostring, Genomic Health

All presenters disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above.  No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

Accreditation Statement:

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (0.075) continuing education units (CEU) which are equivalent to .75 contact hour.

For your credit transcript, please access our website 4 weeks post-completion at and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.

Release Date: 8/31/2017 | Last Modified On: 8/31/2017 | Expires: 8/31/2018

This course has been expired.